 |
|
Chemoradioimmunotherapy for advanced breast cancer: hope for the future?
July 06, 2004Innsbruck, Austria: A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital, Athens, Greece at the 18th Meeting of the European Association for Cancer Research today (Tuesday 6 July 2004).
Advanced breast cancer, with metastases to lung and bone, has a very poor prognosis and current treatment protocols for this stage of disease generally result in survival periods of less than two years. One of the reasons for this poor prognosis is that metastatic cancer cells are less responsive to treatment than primary tumour cells. This is partly caused by the fact that the normal cell death process (apoptosis) is repressed by the overexpression of oncogenes such as bcl-2, HER-2, Raf-1 and cdc25c (these oncogenes are expressed more strongly in metastatic tumour cells), which means that the cells fail to die following treatment with chemotherapy drugs and radiation therapy.
Using metastatic tumour tissue taken from a patient with advanced breast cancer, Dr Giannios's team analysed the cells to determine if known oncogenes were being overexpressed. In addition to finding overexpression of the oncogenes bcl-2, HER-2, Raf-1 and cdc25c they also detected overexpression of DNMT1 (a DNA methyltransferase, involved in DNA replication during cell division, and implicated in cancer development) and they also detected methylation of BRCA1 promoter (a process implicated specifically in the development of breast cancer tumours).
The experimental treatment, termed 'chemoradioimmunotherapy', combined chemotherapy, radiation therapy and immunotherapy in one. The chemotherapy component consisted of vinorelbine-tartrate (a cytotoxic drug used in the treatment of breast (and other) cancers), the radiotherapy component was provided through the addition of high energy radioisotopes, whilst the immunotherapy aspect was achieved by attaching an antibody specific to HER-2 to those radioisotopes, as well as through the inclusion of a separate 21-nucleotide double stranded siRNA ('small interfering RNA') generated against DNMT1.
It was hoped that the novel treatment regime would effectively target the tumour cells by blocking the genetic mechanisms that protect the cells from conventional treatment thereby allowing the chemotherapy and radiation therapy components to exert their cytotoxic effects.
By 24 hours post-treatment there was clear evidence that the treated tumour cells were undergoing significantly greater apoptosis than the untreated controls. Apoptosis was confirmed by the detection of activation of caspase-3-9 (an enzyme involved in apoptosis), inhibition of DNA synthesis and metabolic activity in the tumour cells and the formation of apoptotic bodies. These apoptotic bodies were seen to be phagocytosed (absorbed) by adjacent tumour cells, which resulted in the subsequent apoptosis of the tumour cells through a 'bystander' killing effect.
Several diagnostic tests were employed to determine the molecular basis for the observed success of the chemoradioimmunotherapy treatment. The tests proved that the novel regimen had specifically impacted on the identified oncogenes that are essential to the propagation and perpetuation of the tumour cells. Evidence was found to show 1) there was clear downregulation of HER-2 as a consequence of the action of antiHER-2 scFv antibody; 2) there was re-expression of the tumour suppressor gene BRCA1 as a consequence of the inhibition of the DNMT1 mRNA and; 3) the radioisotopes had induced DNA double strand breaks in the tumour cells. The combination of these molecular actions was responsible for circumvention of chemo- and radioresistant mechanisms in the tumour cells, allowing them to be effectively targeted and damaged by the chemotherapy and radiation therapy components leading to induction of apoptosis.
According to Dr Giannios, "This technique will be very applicable in a clinical setting where treatment difficulties will be limited because, as a tailored and targeted anti-cancer treatment, the treatment will reduce systemic toxicity whilst enhancing the therapeutic index." "Introducing the radiation by linking the radioisotopes to the anti-HER-2 antibody is more efficient than conventional external beam radiotherapy because the radiation is targeted specifically to those breast cancer cells that over-express HER-2/neu, leaving normal cells unaffected and thereby reducing system toxicity", he added.
"These results open the possibility of combining targeted immunotherapy with chemotherapy and radiation therapy to successfully kill metastatic tumour cells", said Dr Giannios. "Theoretically this novel technique should be as effective in other types of cancer that are characterised by hypermethylation of tumour suppressor genes and the overexpression of oncogenes such as HER-2 and bcl-2". "Our next step will be to develop the treatment in patients, and on a bigger scale, in a Phase I clinical trial".
Federation of European Cancer Societies (FECS)
Radiation Therapy Current Events and Radiation Therapy News RSSFamily history of prostate cancer does not affect some treatment outcomes
In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics similar to men with no family history at all, according to a January 1 study in the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology.
What is the mechanism of the chronic radiation enteritis?
The use of radiation therapy to treat cancer inevitably involves exposure of normal tissues.
Research on the effects of stem cell source and patient age on transplantation outcomes
Blood cancers - leukemia, lymphoma, and myeloma - are typically treated with a combination of treatments including chemotherapy, biological therapy, radiation therapy, and stem cell transplantation. Stem cell transplantation is the process by which blood stem cells are collected from a donor, or from the patient prior to chemotherapy, and then infused into the patient after treatment.
Preoperative radiation may improve survival rates in advanced rectal cancer patients
Patients treated with radiation prior to surgery for advanced rectal cancer have fewer instances of cancer recurrence and better overall survival rates, according to a recent Geisinger report.
Breast cancer treatment offers better outcome to women with implants
Women with early-stage breast cancer who have undergone breast augmentation may be treated successfully with a partial-breast radiation treatment called brachytherapy, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Survival of head and neck cancer patients is greatly affected by coexisting ailments
Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital.
Fat injections can improve breast reconstruction -- jury's out on augmentation
Injecting fat after breast reconstruction to correct implant wrinkling or dimpling may be safe and effective to improve breast shape.
OHSU Cancer Institute researcher: radiation, immunotherapy gives greater effectiveness
Oregon Health & Science University Cancer Institute researchers have found the right formula of radiation and immunotherapy for fighting lung cancer tumors in mice, which they hope will translate to better treatment in human lung cancers.
Cancer patients who receive neoadjuvant therapy followed by mastectomy may not need radiation
Early-stage breast cancer patients who exhibit limited lymph node involvement may not require post-surgery radiation therapy (RT) when they receive neoadjuvant chemotherapy before a mastectomy, according to researchers from The University of Texas M. D. Anderson Cancer Center.
OHSU Cancer Institute researchers study breathing during radiation
Oregon Health & Science University researchers have determined exactly how much breathing affects prostate movement during radiation treatment.
More Radiation Therapy Current Events and Radiation Therapy News Articles
| Portal Design in Radiation Therapy, 2nd ed by Byron G. Dasher; Anne Marie Vann Portal Design in Radiation Therapy, 2nd Edition contains over 120 explicit diagrams illustrating the anatomy and lymphatics included in typical treatment portals. In addition, CT and MR anatomy are included, as well as tissue tolerance charts. Descriptions of surrounding anatomy, routes of spread, technical aspects of portal design and typical doses employed for each tumor site are... | |
 | The Physics of Radiation Therapy by Faiz M Khan, Faiz M. Khan Univ. of Minnesota Medical School, Minneapolis. Text focuses solely on radiation therapy physics with particular emphasis on the practical details. Includes new and revised data on 3-D conformal radiation therapy, IMRT, stereotactic radiation therapy, high dose rate brachytherapy, seed implants, and intravascular... |
 | Radiation Therapy Planning by Gunilla C. Bentel All new expanded edition provides step-by-step guidelines on performing the technical aspects of radiation therapy. Important new coverage includes treatment preparation, 3-D treatment planning, dosimetry, new technologies, documentation, and quality assurance. In addition, you'll find added treatment planning guidelines by body region, and an expanded art program including many new 4-color... |
 | A Guide for Delineation of Lymph Nodal Clinical Target Volume in Radiation Therapy Conformal radiotherapy offers the opportunity to enhance precise delivery of high dose radiation to the target volume while maintaining normal tissues doses at acceptable tolerance levels. This technique requires an exact definition of the treatment volumes: gross tumour volume (GTV), clinical target volume (CTV) and planning target volume (PTV). For this reason, it is important to have a very... |
 | Image-Guided Radiation Therapy of Prostate Cancer: Image-Guided Radiation Therapy Answering the need that exists for a single reference to address the practical issues of implementing image guided radiation therapy (IGRT) into prostate cancer treatment, this text... |
 | Principles and Practice of Radiation Therapy by Charles M. Washington, Dennis T. Leaver Learn everything you need to know about radiation therapy with the only comprehensive text written for radiation therapy students by radiation therapists. Principles and Practice of Radiation Therapy is designed to help you understand cancer management, improve clinical techniques for delivering doses of radiation, and apply complex concepts to treatment planning and delivery. This edition... |
 | Radiation Therapy Physics by William R. Hendee, Geoffrey S. Ibbott, Eric G. Hendee The techniques of state-of-the-art radiation therapy have evolved greatly in recent years. Treatment procedures such as conformal and intensity-modulated radiation therapy, high dose-rate and brachytherapy, and image-guided radiation therapy have become standards in radiation therapy clinics around the world. Teaching models for radiation therapy have advanced accordingly, as have the protocols... |
 | Technical Basis of Radiation Therapy: Practical Clinical Applications (Medical Radiology / Radiation Oncology) by L.W. Brady This book, now in its fourth edition, is unique in detailing in depth the technological basis of radiation therapy. Compared with the previous edition, all chapters have been rewritten and updated. In addition, new chapters have been included on various topics, including the use of imaging in treatment planning, second malignant neoplasms due to irradiation, and quality assurance in radiation... |
 | The Chemotherapy & Radiation Therapy Survival Guide (Chemotherapy and Radiation Therapy Survivor's Guide) by Judith McKay, Nancee Hirano |
 | Clinical Target Volumes in Conformal and Intensity Modulated Radiation Therapy Conformal radiation therapy represents a new challenge for radiation oncologists. It offers the prospect of either increasing the radiation dose to target tissues while delivering a similar dose to organs at risk, or reducing the dose to organs at risk while maintaining the dose to target tissues. First, lymph node areas at risk are established using the available data from pathological... |
| © 2009 BrightSurf.com |